Skopek T R, Kort K L, Marino D R, Mittal L V, Umbenhauer D R, Laws G M, Adams S P
Merck Research Laboratories, West Point, Pennsylvania, USA.
Environ Mol Mutagen. 1996;28(4):376-84. doi: 10.1002/(SICI)1098-2280(1996)28:4<376::AID-EM11>3.0.CO;2-C.
Big Blue (BB) and generic B6C3F1 mice were given one to three i.p. injections of 50 mg/kg benzo[a]pyrene (B[a]P) in DMSO every other day to achieve cumulative doses of 50 to 150 mg/kg. Three weeks after treatment, the mutation frequency at the endogenous hprt gene and lacI transgene was measured in splenic T cells. Generic mice given 50, 100, and 150 mg/kg B[a]P displayed induced hprt frequencies (observed hprt frequency minus control frequency) of 5.5 +/- 1.0, 11 +/- 2.0, and 19 +/- 2.6 x 10(-6), respectively (average +/- SEM). In contrast, BB mice given 50 and 150 mg/kg B[a]P displayed induced hprt frequencies of 0.9 +/- 0.6 and 9.1 +/- 1.5 x 10(-6). 32P postlabelling revealed that the lower hprt response in BB mice correlated with lower amounts of BP-DNA adducts in spleen, liver, and lung 24 hours after B[a]P exposure. Western blot analysis of liver samples from B[a]P-treated mice suggests that the reduced adduct load in turn may be due to lower P450 1A1 levels in BB mice. The frequency of induced, nonsectored blue plaques (observed blue plaque frequency minus control frequency) in BB mice receiving 50 and 150 mg/kg B[a]P was 41 +/- 9 and 134 +/- 10 x 10(-6) (15- to 40-fold higher than the induced hprt frequency in the same treated animals). Sectored plaques were observed in both control and B[a]P groups but their frequency showed no relationship to dose (sectored frequency in all groups was approximately 20 x 10(-6)). To test whether persistent DNA adducts in the packaged lambda vector were contributing to the observed blue plaque frequency, purified lambda-LIZ DNA was treated in vitro with B[a]P diol epoxide (BPDE), packaged, and plated on E. coli lawn cells. Treatment with BPDE did not produce significant increases in homogeneous blue plaques, suggesting that the majority of mutants obtained from B[a]P-treated BB mice occurred in vivo. These results indicate that B[a]P exposure produces many more mutations at the lacI transgene than at the endogenous hprt locus.
将蓝色品系(BB)小鼠和普通B6C3F1小鼠每隔一天腹腔注射1至3次50mg/kg溶于二甲基亚砜(DMSO)的苯并[a]芘(B[a]P),以达到累积剂量50至150mg/kg。处理后三周,测量脾T细胞内源性hprt基因和lacI转基因的突变频率。给予50、100和150mg/kg B[a]P的普通小鼠诱导的hprt频率(观察到的hprt频率减去对照频率)分别为5.5±1.0、11±2.0和19±2.6×10⁻⁶(平均值±标准误)。相比之下,给予50和150mg/kg B[a]P的BB小鼠诱导的hprt频率分别为0.9±0.6和9.1±1.5×10⁻⁶。³²P后标记显示,BB小鼠中较低的hprt反应与B[a]P暴露24小时后脾、肝和肺中较低的BP-DNA加合物量相关。对B[a]P处理小鼠的肝脏样本进行蛋白质免疫印迹分析表明,加合物负载量降低可能反过来是由于BB小鼠中较低的细胞色素P450 1A1水平。接受50和150mg/kg B[a]P的BB小鼠中诱导的、无扇形蓝色噬菌斑频率(观察到的蓝色噬菌斑频率减去对照频率)分别为41±9和134±10×10⁻⁶(比相同处理动物中诱导的hprt频率高15至40倍)。在对照和B[a]P组中均观察到扇形噬菌斑,但其频率与剂量无关(所有组中的扇形频率约为20×10⁻⁶)。为了测试包装的λ载体中持续存在的DNA加合物是否导致观察到的蓝色噬菌斑频率,用苯并[a]芘二醇环氧化物(BPDE)体外处理纯化的λ-LIZ DNA,包装后铺在大肠杆菌草坪细胞上。用BPDE处理未导致均匀蓝色噬菌斑显著增加,这表明从B[a]P处理的BB小鼠获得的大多数突变体是在体内发生的。这些结果表明,B[a]P暴露在lacI转基因处产生的突变比在内源性hprt基因座处多得多。